1319736-84-9

Upstream product

• 143409-08-9 (R)-4-acetyl-1-((S)-1-phenylethyl)pyrrolidin-2-one 

Downstream Products

• 143444-74-0 <4R-<1(S*),4R*(S*)>>-4-(1-aminoethyl)-1-(1-phenylethyl)-2-pyrrolidinone 
• 143444-75-1 <4R-<1(S*),4R*(R*)>>-4-(1-aminoethyl)-1-(1-phenylethyl)-2-pyrrolidinone 
• 1319738-01-6 (4R,5R)-5-methyl-4-((7-(3,4,5-trimethoxyphenyl)-1,6-naphthyridine-5-ylamino)methyl)pyrrolidine-2-one 

Relevant academic research and scientific papers

SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS

The invention relates to new substituted naphthyridines of formula (1), as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is selected from among -O-R3 or -NR3R4, R3 is C1-6-alkyl which is substituted by R5 and R6 R5 is selected from hydrogen, branched or linear C1-6-alkyl, C2-6-alkenyl, -C1-6-alkylen-O-C1-3-alkyl, C1-3-haloalkyl, R6 is ring X wherein n is either 0 or 1, and Formula (I) is a either a single or a double bond and wherein A, B, D and E are each independently from one another selected from CH2, CH, C, N, NH, O or S and wherein ring X is attached to the molecule either via position A, B, D or E, wherein said ring X may optionally be further substituted by one, two or three residues each selected individually from the group consisting of -oxo, hydroxy, -C1-3-alkyl, -C1-3-haloalkyl, -O-C1-3-alkyl, -C1-3-alkanol and halogen, and wherein R4, R2, R7, R8, R9, R10, R11 and Q may have the meanings as given in claim 1, as well as pharmaceutical compositions containing these compounds.